We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.76%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$5.72B
AUM Growth
+$1.24B
Cap. Flow
+$622M
Cap. Flow %
10.88%
Top 10 Hldgs %
39.54%
Holding
129
New
28
Increased
37
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$84.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$65.7M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$65.1M
5
PCVX icon
Vaxcyte
PCVX
+$58.5M

Top Sells

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$257M
2
CBAY
Cymabay Therapeutics
CBAY
+$95.1M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.3M
4
ACLX
Arcellx
ACLX
+$38.8M
5
ABBV icon
AbbVie
ABBV
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Miscellaneous 0.72%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
51
DELISTED
Centessa Pharmaceuticals
CNTA
$34.8M 0.61%
+3,083,307
New +$29.2M
LABP
52
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$31.9M 0.56%
1,486,991
– –
OCUL icon
53
Ocular Therapeutix
OCUL
$2.24B
$30.3M 0.53%
+3,324,468
New +$23.6M
TMCI icon
54
Treace Medical Concepts
TMCI
$298M
$30.1M 0.53%
2,304,954
+1,054,549
+84% +$14.1M
CABA icon
55
Cabaletta Bio
CABA
$441M
$29.3M 0.51%
1,716,660
-286,398
-14% -$6.15M
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.28B
$28.8M 0.5%
994,323
+611,063
+159% +$16.6M
IRTC icon
57
iRhythm Holdings
IRTC
$3.69B
$28.4M 0.5%
+245,205
New +$27.6M
ALDX icon
58
Aldeyra Therapeutics
ALDX
$82.6M
$28.1M 0.49%
8,593,586
– –
AUTL
59
Autolus Therapeutics
AUTL
$503M
$27.6M 0.48%
4,330,745
+2,499,578
+137% +$15.6M
ACRV icon
60
Acrivon Therapeutics
ACRV
$78.4M
$21.5M 0.38%
3,007,858
– –
PEPG icon
61
PepGen
PEPG
$200M
$20.7M 0.36%
+1,410,438
New +$16.7M
RVMD icon
62
Revolution Medicines
RVMD
$43.9B
$19.9M 0.35%
618,885
-199,997
-24% -$5.93M
ABBV icon
63
AbbVie
ABBV
$465B
$19.4M 0.34%
106,500
-131,500
-55% -$22.7M
IRON icon
64
PUT
Disc Medicine
IRON
$2.58B
$18.7M 0.33%
+300,000
New +$19.5M
MLTX icon
65
MoonLake Immunotherapeutics
MLTX
$1.04B
$17M 0.3%
339,012
+256,614
+311% +$13.9M
ENGN icon
66
enGene Therapeutics
ENGN
$127M
$16.9M 0.3%
+998,888
New +$12.2M
LIVN icon
67
LivaNova
LIVN
$4.38B
$16.7M 0.29%
+299,000
New +$15.5M
LONA
68
LeonaBio Inc
LONA
$68.2M
$14.8M 0.26%
540,296
– –
TCMD icon
69
Tactile Systems Technology
TCMD
$510M
$14.7M 0.26%
903,085
+195,926
+28% +$2.96M
OBIO icon
70
Orchestra BioMed
OBIO
$363M
$13.4M 0.23%
2,545,881
+113,792
+5% +$771K
AXGN icon
71
Axogen
AXGN
$2.42B
$12.5M 0.22%
1,553,929
+745,549
+92% +$6.68M
EYPT icon
72
EyePoint Inc
EYPT
$316M
$12.2M 0.21%
589,646
– –
ZYME icon
73
Zymeworks
ZYME
$1.86B
$11.3M 0.2%
1,074,807
– –
RAPT
74
DELISTED
RAPT Therapeutics
RAPT
$11M 0.19%
152,934
-114,560
-43% -$15.9M
TYRA icon
75
Tyra Biosciences
TYRA
$1.52B
$11M 0.19%
669,159
+309,159
+86% +$5.07M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Perceptive Advisors held 129 positions worth $5.72B, up 28% from $4.48B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Perceptive Advisors deployed $622M of net new capital in Q1 2024, opening 28 new positions and adding to 37 existing holdings. Its largest new stake was CG Oncology: 1,304,105 shares worth $57.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Arcellx, an estimated $38.8M trimmed.

  • Perceptive Advisors's largest Q1 2024 buy was CG Oncology: 1,304,105 shares worth $57.3M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2024, an estimated $84.9M increase.
  • Perceptive Advisors's biggest Q1 2024 reduction was Arcellx, cutting an estimated $38.8M.
  • Perceptive Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $257M.
  • Perceptive Advisors's ten largest holdings make up 40% of its $5.72B portfolio in Q1 2024.
  • Perceptive Advisors opened 28 new positions and closed 17 in Q1 2024.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $5.72B.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.